Guidance and quality standards Awaiting development

Showing 271 to 280 of 317

Guidance and quality standards awaiting development
Title	Type
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683	Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID 5077]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]	Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer TS ID 10693	Technology appraisal guidance
Tocilizumab for treating systemic sclerosis (ID1396)	Technology appraisal guidance
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Technology appraisal guidance
Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845	Technology appraisal guidance
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]	Technology appraisal guidance